An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma.

  title={An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma.},
  author={Stefano Tartaggia and Anna Meneghello and Ottavia Bellotto and Ariana Soledad Poetto and Martina Zanchetta and Bianca Posocco and David Bunka and Federico Polo and Giuseppe Toffoli},
  journal={The Analyst},
The anticancer drug imatinib is often involved in therapeutic drug monitoring (TDM) studies aimed at improving the treatment of several forms of leukemia and gastrointestinal stromal tumors (GIST). To further implement the TDM of imatinib in clinical practice, we developed a detection assay by using an ssDNA aptamer, which demonstrated excellent selectivity and was not affected by interference from the components of human plasma samples. The efficient binding of imatinib to the aptamer was… 
1 Citations
Optical biosensors - Illuminating the path to personalized drug dosing.
The current state of optical biosensors in personalized dosing with special emphasis on TDM is explored, and an appraisal on recent strategies is provided, and the strengths and challenges of optical sensors are critically evaluated.


Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy.
The new SERS method presented in this preliminary work showed simplicity, short analysis time, good sensitivity, and could be considered a promising platform for TDM of imatinib treatment in a point-of-care setting.
Therapeutic drug monitoring and tyrosine kinase inhibitors.
Although TDM is already being used for imatinib, additional studies are required in order to improve this practice with the inclusion of other TKIs, and to evaluate the usefulness of TDM.
Comparison against current standards of a DNA aptamer for the label‐free quantification of tobramycin in human sera employed for therapeutic drug monitoring
Results show how, using adequate calibration and matrix complexity reduction, DNA aptamer‐based direct assays can assess clinically relevant concentrations of small molecules in patient serum and with good correlation to current standards used in the clinics.
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
This is the first broad-range LC-MS/MS assay covering the major currently in-use TKIs, an improvement over previous methods in terms of convenience, sensitivity, selectivity and throughput, and may contribute to filling the current knowledge gaps in the pharmacokinetics/pharmacodynamics relationships of the latest TKI developed after imatinib.
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
Using an arithmetical approach combining all parameters obtained in imatinib-treated patients, a conclusive approximation of basic pharmacokinetic data is provided for bothImatinib and its main metabolite N-desmethyl-imatinib.
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Applications for TDM during oral targeted therapies may best be reserved for particular situations including lack of therapeutic response, severe or unexpected toxicities, anticipated drug-drug interactions and/or concerns over adherence treatment.
Biosensing Technologies for Therapeutic Drug Monitoring.
The most promising methodologies that, in the author's opinion, will bring TDM towards the next stage of clinical practice in the future are described.
Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib.
The specificity and sensitivity of the ELISA forImatinib should provide a valuable new tool for use in therapeutic drug monitoring and pharmacokinetic studies of imatinib.
Clinical Pharmacokinetics of Imatinib
Pharmacokinetic studies of Imatinib in healthy volunteers and patients with CML, GIST and other cancers show that orally administered imatinib is well absorbed, and has an absolute bioavailability of 98% irrespective of oral dosage form (solution, capsule, tablet) or dosage strength (100mg, 400mg).
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Implications for Therapeutic Drug Monitoring
Current knowledge of the clinical pharmacokinetics and known adverse effects of the TKIs that are available for clinical use are summarized to provide practical guidance on the implications of these data in patient management, in particular with respect to therapeutic drug monitoring.